|Systematic (IUPAC) name|
|Half-life||24-36 hours |
LGD-4033 is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis, currently under development by Ligand Pharmaceuticals.
- Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW et al. (Jan 2013). "The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.". J Gerontol A Biol Sci Med Sci 68: 87–95. PMID 22459616. doi:10.1093/gerona/gls078.
- "Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting" (Press release). San Diego: Ligand Pharmaceuticals. November 20, 2009. Retrieved November 23, 2014.